Is Precision BioSciences, Inc. (DTIL) a Buy, Sell, or Hold?
NASDAQ : DTIL
Precision BioSciences, Inc.
$7.49 USD
$0.07 (0.94%)
- Volume
- 239.58K
- Average Volume
- 410.88K
- Market Capitalization
- $96.08M
- P/E Ratio
- -2.68
- Dividend Yield
- 0.00%
- Price Target
- $19.50
- Year High
- $9.62
- Year Low
- $3.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.82
Company Overview
NASDAQ
Michael Amoroso
Biotechnology
Healthcare
DTIL
68
US
USD
Liquidity Metrics
0.04
12.82
12.82
12.06
0.00
Sales & Valuation
$34.26M
2.13
4.28
-1.50
-2.47
Profitability
-$3.56
-$45.72M
-117.04%
-119.00%
-91.60%
-41.88%
P/E Metrics
-2.68
-0.02
-0.02
Analyst Price Target & Rating
$19.50
$20.00
$19.00
2/5
12 Analysts
-61.59%
Financial Health Scores
-5.93
3/9
$84.41M
$125.92M
$80.63M
-$52.3M
Key Metrics (TTM)
$11.61M
0.26
-0.23
12.82
-91.60%
-30.23%
-27.23%
-66.51%
0 days
Company Executives
| Name | Title |
|---|---|
| John Alexander Kelly | Chief Operating Officer |
| Cassie Gorsuch | Chief Scientific Officer |
| Jefferson J. Smith | Co-Founder & Chief Research Officer |
| Naresh Tanna | Chief of Staff to Chief Executive Officer & Head of Investor Relations |
| Neil Leatherbury | Senior Vice President and Head of Chemistry, Manufacturing & Controls |
| Cindy Atwell | Chief Development & Business Officer |
| Juli Blanche | Chief People Officer |
| Dario Scimeca | General Counsel & Secretary |
| Michael Amoroso | President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About Precision BioSciences, Inc. (NASDAQ:DTIL) Stock
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leuk ... emia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 08:00:00
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene editi
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 07:01:00
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quarter marked a defining moment for Precision BioSciences and the hepatitis B field, with the first clinical biopsy evidence that a therapeutic.
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-31 07:01:00
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the second quarter 2026 and provide a business update on Thursday, August 6, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improvin.
2026-07-27 07:01:00
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced changes to its senior leadership team. Alex Kelly, currently Chief Financial Officer, has been promoted to the newly created role of Chief Operating Officer where he will oversee all key customer-facing functions. Naresh Tanna, currently Vice Preside.
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 07:01:00
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision's Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan.
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
2026-07-08 11:36:14
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2026-06-29 08:00:00
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
2026-06-29 07:01:00
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000® Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions published by FTSE Russell. The annual reconstitution of the Russell U.S. indexes ranks eligible U.S. sto.
Frequently Asked Questions
-
What is the current Precision BioSciences, Inc. (DTIL) stock price?
-
Precision BioSciences, Inc.(NASDAQ:DTIL) stock price is $7.49 in the last trading session. During the trading session, DTIL stock reached the peak price of $9.62 while $3.53 was the lowest point it dropped to. The percentage change in DTIL stock occurred in the recent session was 0.94% while the dollar amount for the price change in DTIL stock was $0.07.
-
DTIL's industry and sector of operation?
-
The NASDAQ listed DTIL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DTIL?
-
John Alexander Kelly | Chief Operating Officer
Cassie Gorsuch | Chief Scientific Officer
Jefferson J. Smith | Co-Founder & Chief Research Officer
Naresh Tanna | Chief of Staff to Chief Executive Officer & Head of Investor Relations
Neil Leatherbury | Senior Vice President and Head of Chemistry, Manufacturing & Controls -
How many employees does DTIL have?
-
Number of DTIL employees currently stands at 68. DTIL operates from 302 East Pettigrew Street, Durham, NC 27701, US.
-
Link for DTIL official website?
-
Official Website of DTIL is: https://www.precisionbiosciences.com
-
How do I contact DTIL?
-
DTIL could be contacted at phone #919 314 5512 and can also be accessed through its website. DTIL operates from 302 East Pettigrew Street, Durham, NC 27701, US.
-
How many shares of DTIL are traded daily?
-
The average number of DTIL shares traded daily for last 3 months was 410.88K.
-
What is the market cap of DTIL currently?
-
The market value of DTIL currently stands at $96.08M with its latest stock price at $7.49